Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel
NASDAQ:ALGS

Aligos Therapeutics Q3 2026 Earnings Date & Estimates

Aligos Therapeutics logo
$5.23 -0.28 (-5.08%)
Closing price 04:00 PM Eastern
Extended Trading
$5.32 +0.09 (+1.63%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aligos Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 4, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Aligos Therapeutics in Q3 2026

Aligos Therapeutics is expected to post earnings of -$2.44 per share on revenue of $4.85 million. In the same quarter a year earlier Aligos Therapeutics reported -$3.04 per share on revenue of $0.74 million. Aligos Therapeutics last reported on August 6, 2026, posting -$0.14 per share and beating the -$1.09 consensus estimate. Aligos Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$2.44
Expected Revenue
$4.85 million
Prior-Year EPS
-$3.04
Prior-Year Revenue
$0.74 million
Expected Revenue Growth
+554.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.14 (Beat by +$0.95)
Last Quarter Revenue
$27.78 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Aligos Therapeutics Q3 2026 Earnings FAQ

Aligos Therapeutics (NASDAQ:ALGS) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Aligos Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Aligos Therapeutics to post earnings of -$2.44 per share for Q3 2026.

The consensus revenue estimate for Aligos Therapeutics is $4.85 million for Q3 2026.

Aligos Therapeutics Earnings Headlines

Aligos Therapeutics, Inc. (ALGS) - What Are Researchers Saying About This Stock?
October 12 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109640
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting 2026
October 6, 2026  |  marketscreener.comM
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.tc pixel
October 14 at 1:00 AM  |  Brownstone Research (Ad)
Aligos Therapeutics To Present HBV, HDV Programs At AASLD 2026
October 6, 2026  |  rttnews.comhttps://www.rttnews.com/3696670/aligos-therapeutics-to-present-hbv-hdv-programs-at-aasld-2026.aspx
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
October 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374991/0/en/aligos-therapeutics-announces-five-abstracts-accepted-for-presentation-at-the-liver-meeting-2026.html
Aligos Therapeutics Amends Long-Term Headquarters Lease Agreement
September 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/aligos-therapeutics-amends-long-term-headquarters-lease-agreement?utm_source=marketbeat.com&utm_medium=referral
See More Aligos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email.

About Aligos Therapeutics

Aligos Therapeutics (NASDAQ:ALGS) is a clinical-stage biopharmaceutical company focused on developing medicines for chronic liver diseases and other viral infections. The company’s research programs are designed to address significant unmet needs in conditions including chronic hepatitis B virus (HBV) infection, hepatitis D virus (HDV) infection and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis.

Aligos’ pipeline includes investigational therapies intended to target different stages of disease biology. Its HBV programs include capsid assembly modulators, such as ALG-000184, which are designed to interfere with the virus’s replication cycle. The company has also developed ALG-055009, an oral thyroid hormone receptor beta agonist being evaluated for potential use in MASH. Aligos has pursued additional antiviral research, including programs directed at coronaviruses and other viral diseases.

Founded in 2018, Aligos Therapeutics is headquartered in South San Francisco, California. The company conducts research and clinical development through collaborations and clinical studies intended to support the advancement of its investigational medicines in global markets. Its programs remain subject to clinical testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

View Aligos Therapeutics Profile
Earnings Tools